References
- Sandberg-Gertzén H, Ryde H, Järnerot G. Absorption and excretion of a single 1 g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18: 107–11
- Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-Amino-salicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062–70
- Dew MJ, Hughes PJ, Lee MG, Evan BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405–8
- Van Hogezand RA, Van Hees PAM, Zwanenburg B, Van Rossum JM, Van Tongeren JUM. Disposition of disodium azo-disalicylate in healthy subjects. Gastroenterology 1985; 88: 717–22
- Klotz U, Maicr KE, Fischer C, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Drug Res 1985; 35: 636–9
- Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol 1988; 23: 107–12
- Van Hees PAM, Tuinte JHM, van Rossum JM, van Tongeren JIIM. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 1979; 20: 300–4
- Christensen LA, Slot O, Sanchez G, et al. Release of 5-aminosalicylic acid from Pcntasa® during normal and accelerated transit time. Br .1 Clin Pharmacol 1987; 23: 365–9
- Rijk MCM, van Hogezand RA, van Schaik A, Van Tongeren JHM. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol 1989; 24: 1179–85
- Klotz U, Maicr KE, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Drug Res 1985; 3: 636–9
- Lauritsen K, Staerk Laursen L, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988; 29: 974–82
- Dull BJ, Salata K, Goldman P. Role of intestinal flora in the acetylation of sulphasalazine metabolites. Biochem Pharmacol 1987; 36: 3772–4
- Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acethylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38–41
- Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 738–40
- Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196–200
- Truelovc SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutical trial. Br Med J 1955; 2: 1041–8
- van Hees PAM, van Elteren Ph, van Lier HJJ, van Tongeren JHM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–86
- van Hogezand RA, van Schaik A, van Hees PAM, Van Tongeren JHM. Stability of disodium azodisalicylate and metabolites in urine and faeces stored at different temperatures. 5-Aminosalicylie acid compounds. Pharmacokinetic and clinical aspects, RA van Hogezand. thesis, University of Nijmegen, Nijmegen 1986
- Cummings JII, Wiggins HS. Transit through the gut measured by analysis of a single stool. Gut 1976; 17: 219–23
- Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radioopaque markers. Gut 1969; 10: 842–7
- Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271–6
- Willoughby CP, Piris J, Truelove SC. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 1980; 15: 715–9
- Binder V, Halskov S, Hvidberg E, et al. A controlled study of 5-acctyl-aminosalicylic acid (5-AC-ASA) as enema in ulcerative colitis [abstract]. Scand J Gastroenterol 1981; 16: 1122
- van Hogezand RA, van Hees PAM, van Gorp JPWM, et al. Effect of 5-aminosalicylic acid (mesalazine) and acetyl-5-aminosalicylic acid (ac-mesalazine) suppositories in patients with idiopathic proctitis. A double blind study. Aliment Pharmacol Ther 1988; 2: 33–40
- Mulder CJJ, Tytgat NJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylic acid and sulphasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449–53